Latest Neurimmune News & Updates

See the latest news and media coverage for Neurimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Neurimmune

Biopharmaceutical company developing antibody therapeutics

neurimmune.com
Headquarters
Zurich Schlieren, Switzerland
Founded year
2006
Company type
Private company
Number of employees
60–200

Last updated

Latest news about Neurimmune

In short: Neurimmune expanded its protein aggregation pipeline and strategic partnerships, notably securing a $780 million license agreement with AstraZeneca.

Company announcements

  • Neurimmune

    AL-S Pharma reports positive Phase 2 AP-101 results for ALS

    Study met safety endpoints with prolonged survival, delayed ventilatory support, and functional stabilization. Plans advance for confirmatory Phase 3 study.

  • Neurimmune

    Neurimmune expands collaboration with AstraZeneca for NI009

    Exclusive global license agreement targets lambda light chain fibrils in AL amyloidosis. Neurimmune receives upfront payment, up to $780 million milestones, and royalties.

  • Neurimmune

    Neurimmune doses first patient in Phase 2 cliramitug study

    The single-arm, multicenter NI006-102 study evaluates pharmacodynamics and safety of re-treatment in ATTR-CM patients. It assesses changes in cardiac amyloid load, structure, and function.

  • Neurimmune

    AL-S Pharma appoints Prof. Dr. Angela Genge as CMO

    Renowned ALS neurologist from McGill University will lead AP-101 late-stage development. She served as global principal investigator since 2016.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Neurimmune

Track Neurimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurimmune competitors & trending companies

Browse news for competitors to Neurimmune and other trending companies.